Drug repurposing to target TGF-β in chemoresistant high-grade serous ovarian cancer

被引：0
|
作者：
Wong-Brown, Michelle W. Y.
Johnson, Zlata
Salem, Saad
Matthews, Bayley G.
Ford, Caroline E.
Marsh, Deborah J.
Bowden, Nikola A.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-C041
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C041
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Drugs Repurposing in High-Grade Serous Ovarian Cancer
    Torralba, Manuel
    Farra, Rossella
    Maddaloni, Marianna
    Grassi, Mario
    Dapas, Barbara
    Grassi, Gabriele
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (42) : 7222 - 7233
  • [2] Investigation of DNA Repair and the Epigenome in Chemoresistant High-Grade Serous Ovarian Cancer
    Wong-Brown, Michelle W.
    Lombard, Janine
    van der Westhuizen, Andre
    Bowden, Nikola A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 29 - 30
  • [3] Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer
    Matthews, Bayley G.
    Bowden, Nikola A.
    Wong-Brown, Michelle W.
    CANCERS, 2021, 13 (23)
  • [4] Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer
    Freimund, Alison E.
    Beach, Jessica A.
    Christie, Elizabeth L.
    Bowtell, David D. L.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2018, 32 (06) : 983 - +
  • [5] Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancer
    Matthews, Bayley
    Wong-Brown, Michelle
    Liu, Dongli
    Yee, Christine
    Dickson, Kristie-Ann
    Schneider, Jennifer
    Islam, Saiful
    Head, Richard
    Martin, Jennifer H.
    Ford, Caroline E.
    Marsh, Deborah J.
    Bowden, Nikola A.
    MOLECULAR THERAPY ONCOLOGY, 2024, 32 (04):
  • [6] Mechanistic role of nelfinavir as drug-repurposing strategy against high-grade serous ovarian cancer.
    Subeha, Mahbuba R.
    Goyeneche, Alicia A.
    Telleria, Carlos M.
    CANCER RESEARCH, 2021, 81 (13)
  • [7] Credentialing ERalpha as target in high-grade serous ovarian cancer.
    Oesterreich, Steffi
    Anderson, Courtney L.
    Sikora, Matthew J.
    Boisen, Michelle M.
    Ma, Tianzhou
    Tseng, George
    Chandran, Uma
    Christie, Alec
    Park, Yongseok
    Luthra, Soumya
    Haluska, Paul
    Mantia-Smaldone, Gina
    Odunsi, Kunle
    McLean, Karen
    Lee, Adrian
    Ellshaev, Esther
    Edwards, Robert P.
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 122 - 122
  • [8] Characterizing chromosome instability in chemonaive, chemosensitive, and chemoresistant high-grade serous ovarian cancer.
    Morden, Claire
    Farrell, Ally
    Sliwowski, Mirka
    Lichtensztejn, Zelda
    Nachtigal, Mark
    McManus, Kirk
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 47 - 48
  • [9] TOP2A Promotes Tumorigenesis of High-grade Serous Ovarian Cancer by Regulating the TGF-β/Smad Pathway
    Gao, Yan
    Zhao, Hongyu
    Ren, Meng
    Chen, Qi
    Li, Jie
    Li, Zhefeng
    Yin, Chenghong
    Yue, Wentao
    JOURNAL OF CANCER, 2020, 11 (14): : 4181 - 4192
  • [10] Screening of drug candidates to repurpose for high-grade serous ovarian cancer treatment
    Bay, Marie L.
    Skorda, Aikaterini
    Rasmussen, Benita S.
    Arias, Jaume R.
    Lauridsen, Anna R.
    Huhtinen, Kaisa
    Hautaniemi, Sampsa
    Hynninen, Johanna
    Kallunki, Tuula
    CANCER RESEARCH, 2024, 84 (05)
12345